IMARC Group has recently released a new research study titled “United States Cancer Immunotherapy Market Report by Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, and Others), End User (Hospitals, Cancer Research Centers, Clinics, and Others), and Region 2026-2034” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States cancer immunotherapy market size was valued at USD 35,271.7 Million in 2025. It is projected to grow at a CAGR of 9.84% during the forecast period 2026-2034, reaching USD 82,067.9 Million by 2034. Market growth is driven by advancements in research and development, increasing cancer incidence, investments in healthcare infrastructure, regulatory support, and collaborations to enhance personalized treatment options.

Study Assumption Years

• Base Year: 2025

• Historical Year/Period: 2020-2025

• Forecast Year/Period: 2026-2034

United States Cancer Immunotherapy Market Key Takeaways

• Current Market Size: USD 35,271.7 Million (2025)

• CAGR: 9.84% (2026-2034)

• Forecast Period: 2026-2034

• The market benefits from continued R&D leading to discovery and development of novel immunotherapies like immune checkpoint inhibitors and CAR-T cell therapies.

• Rising cancer prevalence and an aging population in the US are boosting demand for immunotherapy treatments.

• Robust healthcare infrastructure and increasing investments in R&D facilitate market growth.

• Leading pharmaceutical companies and biotech firms are heavily investing in innovative product development and commercialization.

Sample Request Link: https://www.imarcgroup.com/united-states-cancer-immunotherapy-market/requestsample

To get more information on this market,  Request Sample

United States Cancer Immunotherapy Market Growth Factors

The United States cancer immunotherapy market is propelled by rapid advancements in research and development (R&D). Breakthroughs have led to novel immunotherapies including immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines, expanding the therapeutic arsenal against cancer. These R&D activities have accelerated innovation, allowing for more effective and targeted treatments, thereby driving increased adoption and market expansion.

The increasing prevalence of cancer in the United States represents a significant market driver. The country has experienced a rising incidence of cancer cases, creating a heightened demand for effective treatment options such as immunotherapy. This trend, coupled with the growing aging population—where cancer is more common—contributes strongly to the sustained growth of this market over the forecast period.

Substantial investments in healthcare infrastructure and supportive regulatory frameworks foster an environment conducive to market growth. The robust healthcare infrastructure in the U.S., combined with burgeoning investments in R&D, provide critical support for immunotherapy development and commercialization. Furthermore, collaborations among industry stakeholders and increased awareness around personalized treatment options enhance market dynamics positively.

United States Cancer Immunotherapy Market Segmentation

Breakup by therapy type:

• Monoclonal Antibodies: Target specific cancer cells by recognizing and binding to unique antigens.

• Cancer Vaccines: Stimulate the immune system to recognize and attack cancer cells.

• Checkpoint Inhibitors: Block proteins that prevent immune cells from attacking cancer cells.

• Immunomodulators: Modify immune responses to enhance the body's ability to fight cancer.

• Others

Breakup by Application:

• Lung Cancer: Immunotherapy treatments targeted for lung cancer patients.

• Breast Cancer: Therapies designed to treat breast cancer using immune system activation.

• Colorectal Cancer: Immunotherapy specific to colorectal cancer treatment.

• Melanoma: Utilize immune-based therapies for managing melanoma.

• Prostate Cancer: Immune-directed therapies focused on prostate cancer.

• Head and Neck Cancer: Treatments using immunotherapy for cancers in head and neck regions.

• Others: Cover applications in other cancer types.

Breakup by End User:

• Hospitals: Primary healthcare institutions administering cancer immunotherapy.

• Cancer Research Centers: Specialized centers engaged in cancer immunotherapy research and treatment.

• Clinics: Outpatient facilities providing immunotherapy services.

• Others

Regional Insights

The report segments the United States market into Northeast, Midwest, South, and West regions.

Competitive Landscape

The market research report covers a comprehensive competitive landscape analysis including market structure, key player positioning, winning strategies, competitive dashboards, and company evaluation quadrants. Detailed profiles of all major companies have been provided.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302